Early detection, diagnosis, and treatment of newborn diseases are critically important. Timely newborn screening can prevent death and significantly improve patient care outcomes by ensuring infants with serious metabolic and hereditary disorders are identified as early as possible.
CLSI Newborn Screening (NBS) laboratory standards support screening programs worldwide by providing clear test collection instructions and guidance on methods used to detect a wide range of metabolic and hereditary conditions. These standards help promote consistency, accuracy, and reliability across the newborn screening continuum, from specimen collection through testing and follow‑up.
All CLSI NBS standards are developed through CLSI’s internationally recognized, consensus‑based process. This collaborative approach brings together experts from public health, clinical laboratories, industry, and government to develop practical, unbiased guidance that reflects current science, real‑world practice, and the evolving needs of newborn screening programs worldwide.
